SAT-519 Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in a Subset of Younger Postmenopausal Women with Osteoporosis at High Risk for Fracture Representative of Covered Commercial Insurance Enrollees

Abaloparatide (ABL) is a novel, selective activator of the PTH1 receptor signaling pathway. In the 18-month Phase 3 ACTIVE study in women with postmenopausal osteoporosis (NCT01343004), ABL significantly increased bone mineral density (BMD), and decreased the risk of vertebral (VF), nonvertebral (NV...

Descripción completa

Detalles Bibliográficos
Autores principales: Saag, Kenneth, Williams, Setareh, Wang, Yamei, Weiss, Richard, Cauley, Jane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Bone and Mineral Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552091/
http://dx.doi.org/10.1210/js.2019-SAT-519

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552091/
http://dx.doi.org/10.1210/js.2019-SAT-519

Ejemplares similares